A Year into the Pandemic: How the FDA’s CDRH Is Prioritizing Its Workload and Looking Ahead

Read about how CDRH has worked to respond to the COVID-19 public health emergency and its priorities looking ahead.

If your email program has trouble displaying this email, view as a webpage. A Year into the Pandemic: How the FDA's Center for Devices and Radiological Health Is Prioritizing Its Workload and Looking Ahead Throughout the COVID-19 public health emergency, staff at the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) have worked tirelessly and strategically to meet unprecedented workload demands and to provide access to high-quality, critical products that are essential in protecting the public health. The FDA authorized a record number of novel medical devices in 2020 and has authorized 10 times more Emergency Use Authorizations (EUAs) during COVID-19 than all other previous public health emergencies combined. While CDRH continues to prioritize and triage work using existing resources to focus on the COVID-19 response, this is causing delays in other work. Read More Questions? If you have questions, contact the Division of Industry and Consumer Education.

Follow us on Twitter at @FDADeviceInfo Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA